AGP Executive Report
Last update: 4 hours agoChikungunya Vaccine: UK regulators have withdrawn authorization for Valneva’s IXCHIQ after a safety-data review. The company says the decision was not prompted by a newly identified safety issue; approvals in the EU, Canada, Brazil and other markets remain unchanged. The vaccine’s U.S. license was suspended in 2025.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.